Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
Earnings Data
Report Date
Feb 12, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.74Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and expansion in global markets for Eurvipath and Skytrofa, regulatory approvals, and a positive operating profit. However, challenges remain with the conversion rate for insurance approvals and increased SG&A expenses due to commercial expansion. Foreign currency impacts also affected revenue growth.Company Guidance
Strong Global Launch of Eurvipath
Eurvipath achieved €143 million in revenue for Q3, with over 4,250 patients prescribed in the US by more than 2,000 healthcare providers. Insurance approval rates are around 70%, and Eurvipath is available in over 30 countries.
Positive Operating Profit
Ascendis Pharma reported a positive operating profit of €11 million in Q3, indicating a transformation in their financial profile with sustained revenue and cash flow growth.
Regulatory Approvals and Progress
FDA approval for TransCon Growth Hormone for adult growth hormone deficiency in the US and MAA authorization in the EU for pediatric growth hormone deficiency. TransCon CNP is under priority review in the US with a PDUFA date of November 30.
Expansion of Commercial Activities
Skytrofa revenue was €51 million, and the company initiated a Phase 3 basket trial for Skytrofa. TransCon CNP achieved significant trial results showing improvement in linear growth and other health metrics.
ASND Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ASND Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 12, 2025 | $199.22 | $206.45 | +3.63% |
Aug 07, 2025 | $190.35 | $191.49 | +0.60% |
May 01, 2025 | $167.47 | $172.06 | +2.74% |
Feb 12, 2025 | $126.14 | $142.49 | +12.96% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ascendis Pharma (ASND) report earnings?
Ascendis Pharma (ASND) is schdueled to report earning on Feb 12, 2026, TBA (Confirmed).
What is Ascendis Pharma (ASND) earnings time?
Ascendis Pharma (ASND) earnings time is at Feb 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ASND EPS forecast?
ASND EPS forecast for the fiscal quarter 2025 (Q4) is -0.1.